ALNY Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

$173.69  -0.94 (-0.54%)
As of 06/24/2021 15:59:54 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/28/2004
Outstanding shares:  117,545,040
Average volume:  703,651
Market cap:   $20,329,414,668
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    02043Q107
ISIN:        US02043Q1076
Sedol:      B00FWN1
Valuation   (See tab for details)
PE ratio:   -23.42
PB ratio:   22.12
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy